assessment identifies factors associated with increased risk. The 2019 update included a section on principles of cancer risk assessment and counseling for individuals with potentially increased risk, which can guide shared decision-making regarding the need
Search Results
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Featured Updates to the NCCN Guidelines
Samir Gupta, Dawn Provenzale, Xavier Llor, Amy L. Halverson, William Grady, Daniel C. Chung, Sigurdis Haraldsdottir, Arnold J. Markowitz, Thomas P. Slavin Jr, Heather Hampel, CGC, Reid M. Ness, Jennifer M. Weiss, Dennis J. Ahnen, Lee-may Chen, Gregory Cooper, Dayna S. Early, Francis M. Giardiello, Michael J. Hall, Stanley R. Hamilton, Priyanka Kanth, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, June Mikkelson, CGC, Shajan Peter, Scott E. Regenbogen, Mary A. Dwyer, CGC, and Ndiya Ogba
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021
Featured Updates to the NCCN Guidelines
Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O’Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, and Hema Sundar
, and allowing for a shared decision-making with the patient and/or caregiver. Although typically a thorough CGA is performed by a geriatric trained clinician, many of the tools can be applied to routine practice and conducted by providers without any
Elizabeth A. Nardi, Lisa Korin Lentz, Katherine Winckworth-Prejsnar, Amy P. Abernethy, and Robert W. Carlson
not acting in isolation. 22 In turn, this can help with shared decision-making, leading to patients making informed choices. Technology, it seems, should be a trust broker and accelerator. 23 Disparate data sources, such as EHRs, administrative and
Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider
are generally low and include significant bleeding in 1% to 2.8% of cases, pneumothorax in 4%, and hypoxia/bronchospasm in 9%. 27 Shared decision-making with patients is essential to review the risks/benefits value of this procedure for pulmonary
Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh
pathological features alone or initial observation with salvage RT in the event of biochemical recurrence remains a complex and controversial question that should be addressed with shared decision-making. The authors have disclosed that they have no
Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff
lower breast cancer risk than premenopausal survivors (HR, 0.47; 95% CI, 0.23–0.94), indicating that exogenous hormones do not fully mirror the role of endogenous hormones in the development of breast cancer. 83 Using shared decision-making, providers
Timothy J. Wilt and Philipp Dahm
decision making on cancer screening—a systematic review . Washington, DC : Department of Veterans Affairs (US) ; 2014 . 34. Carlsson S Assel M Sjoberg D . Influence of blood prostate specific antigen levels at age 60 on benefits and harms of
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Featured Updates to the NCCN Guidelines
Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas Galloway, Jessica L. Geiger, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, Panayiotis S. Savvides, David Schwartz, Jatin P. Shah, David Sher, Maie St. John, Randal S. Weber, Gregory Weinstein, Frank Worden, Justine Yang Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow
decreased over time. Clinicians and patients should be involved in shared decision-making, in a multidisciplinary context, to individualize treatment of oropharyngeal squamous cell carcinoma.” 65 Additional randomized trials of minimally invasive transoral
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
chemotherapy in an individual patient typically depends on the efficacy and tolerability and shared decision-making between the treating physician and patient. Most patients will be candidates for multiple lines of systemic therapies for palliation. At each
Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar
major cytogenetic response (MCyR) at 3 months or CCyR at 12 months. In patients with >0.1%–1% BCR-ABL1 IS at 12 months, shared decision-making is recommended depending on the goal of therapy in individual patients (longer-term survival vs TFR). As
